01—Abstract
Summary
Summary of the 10-Q filed April 25, 2024. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. reported first-quarter 2024 net sales of $695.4 milliona, down from $716.6 million in the same period of 2023, with the company citing lower sales of certain high-value product offerings in its Proprietary Products segment, partially offset by growth in Contract-Manufactured Products.
Net income fell to $115.3 millionb from $140.0 million, and diluted earnings per share were $1.55 compared with $1.85. Consolidated gross profit declined to $230.2 million, and gross profit margin fell to 33.1% from 37.9%, driven by lower sales volume and an unfavorable product mix in Proprietary Products. Operating profit decreased to $122.8 million from $155.3 million, and the prior-year quarter included a $9.4 million loss on the disposal of a plant that did not recur.
Cash and cash equivalents declined to $601.8 millionc from $853.9 million at year-end 2023, primarily because of $267.0 million of share repurchases and $90.6 million of capital expenditures, which the company attributed to additional manufacturing capacity to meet customer demand. Net cash provided by operating activities was $118.2 million, compared with $138.1 million a year earlier. Total debt was $206.2 million, the company had no outstanding borrowings under its $500.0 million revolving credit facility, and it stated it was in compliance with all debt covenants.
Management stated that cash on hand, operating cash flow and credit facility availability will be adequate for foreseeable liquidity needs. The company repurchased 729,679 shares for $267.0 milliond during the quarter, leaving $294.7 million available under its $1.0 billion repurchase program. Working capital decreased to $1,044.5 million from $1,264.6 million.
02—Key points
Key Highlights
- Net sales were $695.4 million, down $21.2 million or 3.0% from $716.6 million, with Proprietary Products sales down 4.0% and Contract-Manufactured Products sales up 1.8%.
- Operating profit fell to $122.8 million from $155.3 million, and operating profit margin declined to 17.7% from 21.7%.
- Diluted EPS was $1.55, compared with $1.85 in the first quarter of 2023; net income was $115.3 million versus $140.0 million.
- Gross profit margin contracted to 33.1% from 37.9%, reflecting lower sales volume and an unfavorable product mix in Proprietary Products.
- The company repurchased $267.0 million of common stock (729,679 shares at an average price of $365.87), leaving $294.7 million available under its $1.0 billion program.
- Cash and cash equivalents decreased to $601.8 million from $853.9 million, while capital expenditures of $90.6 million were directed toward additional manufacturing capacity.
- No borrowings were outstanding under the $500.0 million revolving credit facility at March 31, 2024, and the company was in compliance with all debt covenants.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, West Pharmaceutical Services kept $0.17.
- Revenue$695.4M100.0%
- Cost of revenue−$465.2M66.9%
- Gross profit$230.2M33.1%
- Operating costs−$107.4M15.4%
- Operating income$122.8M17.7%
- Interest, other & tax−$7.5M1.1%
- Net income$115.3M16.6%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 25, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $695.40M$716.60M | −3.0% |
| Cost of Revenue | $465.20M$445.30M | +4.5% |
| Gross Profit | $230.20M$271.30M | −15.1% |
| R&D Expenses | $17.60M$17.10M | +2.9% |
| SG&A Expenses | $86.70M$86.00M | +0.8% |
| Operating Income | $122.80M$155.30M | −20.9% |
| Interest Expense | $1.60M$2.20M | −27.3% |
| Net Income | $115.30M$140.00M | −17.6% |
| EPS (Basic) | $1.57$1.88 | −16.5% |
| EPS (Diluted) | $1.55$1.85 | −16.2% |
| Shares Outstanding (Basic) | 73.50M74.50M | −1.3% |
| Shares Outstanding (Diluted) | 74.30M75.70M | −1.8% |
05—Questions
Frequently Asked Questions
Why did West Pharmaceutical's sales and profits decline in the first quarter of 2024?
Consolidated net sales fell 3.0%, driven by a 4.0% decline in Proprietary Products, which the company attributed mainly to lower sales of certain high-value product offerings, including FluroTec and Westar components, and fewer standard components. Gross profit in that segment fell as a result of lower sales volume and an unfavorable product mix, partly offset by higher sales prices.
How much cash did West return to shareholders and how is its cash position changing?
During the quarter, West repurchased $267.0 million of common stock and paid $14.7 million in dividends. Cash and cash equivalents fell to $601.8 million from $853.9 million at December 31, 2023, reflecting these repurchases and $90.6 million of capital expenditures, partly offset by $118.2 million of operating cash flow.
Is West's debt position a concern for investors?
Total debt was $206.2 million at March 31, 2024, down slightly from $206.8 million, and the $500.0 million revolving credit facility had no outstanding borrowings, leaving $497.6 million of borrowing capacity. The company stated it was in compliance with all debt covenants and that its cash, operating cash flow and credit facility should cover foreseeable liquidity needs.
What drove the drop in gross margin, and did the company pursue cost reductions?
Consolidated gross profit margin decreased to 33.1% from 37.9%. Proprietary Products margin fell to 37.0% from 42.5% due to lower volume and unfavorable mix, while Contract-Manufactured Products margin fell to 17.0% from 17.6% due to inflationary pressures, mainly compensation costs. The filing also references a 2022 restructuring plan, with remaining restructuring obligations of $2.7 million at March 31, 2024.
06—Continue